KRASG12C-positive NSCLC and CRC
Two-dose, inactivated vaccine
The vaccine is easily distributed and stored.
While it has a reported 79% efficacy when administered per protocol, it is associated with a lower cost that could be attractive to low-income countries.
Access our global intelligence, advanced analytics and global team of experts.